$OXGN Recent News Herbalife tumbles on FTC probe; Plug

New Post Public Reply Private Reply Replies (0) Message Board

Jan 5, 2015 at 9:36 AM

$OXGN Recent News

Herbalife tumbles on FTC probe; Plug Power rebounds 3:30 p.m. March 12, 2014 - Sue Chang
Oxigene shares more than double on ovarian cancer treatment results 9:58 a.m. March 12, 2014 - Russ Britt
Stock futures pulled lower by China, Ukraine worries 8:23 a.m. March 12, 2014 - William L. Watts
Plug plunges, Ukraine pops and how Twitter traded the bull market 8:09 a.m. March 12, 2014 - Shawn Langlois
Oxigene shares surge after positive clinical trial 7:39 a.m. March 12, 2014 - Saumya Vaishampayan
VeriFone shares surge after earnings, outlook 4:22 p.m. March 11, 2014 - Wallace Witkowski
Oxigene soars on ovarian cancer drug results 4:05 p.m. March 11, 2014 - MarketWatch.com
Oxigene shares jump 122% to $5.37 on study result 4:00 p.m. March 11, 2014 - Wallace Witkowski
Monday’s biggest gaining and declining stocks 5:50 p.m. June 6, 2011 - Kate Gibson
Exelixis, Sunesis lead drug stocks lower 2:42 p.m. June 6, 2011 - Val Brickates Kennedy
Oxigene soars on Nasdaq update 8:46 a.m. June 6, 2011 - Val Brickates Kennedy
U.S. stock futures drift; Apple’s Jobs ahead 8:04 a.m. June 6, 2011 - Kate Gibson
Diet-drug makers grab sector spotlight 2:53 p.m. June 3, 2011 - Val Brickates Kennedy
Oxigene rallies 30% ahead of study presentations 11:39 a.m. June 3, 2011 - Val Brickates Kennedy

Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta 6:00 a.m. Dec. 5, 2014 - TheStreet.com
Which Chemotherapy Should OXiGENE Test Their Zybrestat+Avastin Combo Against? 11:42 a.m. Nov. 17, 2014 - Seeking Alpha
OXiGENE: Q3 Earnings And Avastin Approval, Bull Thesis Reiterated 4:20 p.m. Nov. 14, 2014 - Seeking Alpha
Oxigene: Why I Think This Risky Biotech Is A Speculative Buy 9:15 a.m. Nov. 14, 2014 - Seeking Alpha
10-Q: OXIGENE INC 10:30 a.m. Nov. 13, 2014 - Edgar Online - (EDG = 10Q, 10K)
OXiGENE (OXGN) CEO Dr. Dave Chaplin on Q3 2014 Results - Earnings Call Transcript 9:27 p.m. Nov. 12, 2014 - Seeking Alpha
OXiGENE (OXGN) Q3 2014 Results - Earnings Call Webcast 4:25 p.m. Nov. 12, 2014 - Seeking Alpha
Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data 5:12 a.m. Nov. 12, 2014 - TheStreet.com
Update: OXiGENE Presents Zybrestat/Avastin Data, Bull Thesis Remains Intact 5:56 a.m. Nov. 11, 2014 - Seeking Alpha
OxiGene presents Phase 2 data on fosbretabulin 12:31 p.m. Nov. 10, 2014 - Seeking Alpha
Lower Your Expectations For OXiGENE's Presentation At The November 8 International Gynecologic Cancer Society Meeting 10:15 a.m. Nov. 6, 2014 - Seeking Alpha
Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta 7:28 a.m. Oct. 24, 2014 - TheStreet.com
Update: OXiGENE Initiates Clinical Trial -- Shares Rise 6:35 a.m. Sept. 18, 2014 - Seeking Alpha
Update: OXiGENE Earnings - Q2 Miss Challenges My Patience 11:48 a.m. Aug. 6, 2014 - Seeking Alpha
OXiGENE's (OXGN) CEO David Chaplin on Q2 2014 Results - Earnings Call Transcript 7:29 p.m. Aug. 5, 2014 - Seeking Alpha
OXiGENE (OXGN) Q2 2014 Results - Earnings Call Webcast 3:25 p.m. Aug. 5, 2014 - Seeking Alpha
Update: CEO Departure And Recent Capital Raise At OXiGENE Reaffirms Bull Thesis 2:00 p.m. July 28, 2014 - Seeking Alpha
10-Q: OXIGENE INC 2:44 p.m. May 8, 2014 - Edgar Online - (EDG = 10Q, 10K)
OXiGENE's (OXGN) CEO Peter Langecker on Q1 2014 Results - Earnings Call Transcript 7:21 p.m. May 6, 2014 - Seeking Alpha
Q1 2014 O Xi Gene, Inc Earnings Conference Call (OXGN) Q1 2014 Results - Earnings Call Webcast 3:25 p.m. May 6, 2014 - Seeking Alpha

OXiGENE Announces Preclinical Poster Presentation on OXi4503 at Upcoming American Society of Hematology Meeting 8:01 a.m. Nov. 20, 2014 - GlobeNewswire
OXiGENE Announces Issuance of European Patent for OXi4503 in Acute Myeloid Leukemia and other Myeloid Malignancies 4:01 p.m. Nov. 17, 2014 - GlobeNewswire
OXiGENE Reports Third Quarter 2014 Financial Results 4:04 p.m. Nov. 12, 2014 - GlobeNewswire
OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer 3:01 a.m. Nov. 10, 2014 - GlobeNewswire
OXiGENE Announces Third Quarter 2014 Earnings Conference Call and Webcast 8:16 a.m. Oct. 22, 2014 - GlobeNewswire
OXiGENE Announces First Patient Enrolled in Phase 1b/2 Study of Fosbretabulin Combined With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer 3:01 p.m. Oct. 7, 2014 - GlobeNewswire
OXiGENE Announces Presentation of Data From the Phase 2 GOG186I Study at the 15th Biennial Meeting of the International Gynecologic Cancer Society 3:02 p.m. Oct. 6, 2014 - GlobeNewswire
OXiGENE Initiates Phase 2 Study of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors 3:01 p.m. Sept. 17, 2014 - GlobeNewswire
OXiGENE Announces Presentation at the Rodman and Renshaw Conference on September 9 3:01 p.m. Aug. 26, 2014 - GlobeNewswire
OXiGENE Reports Second Quarter 2014 Financial Results 3:01 p.m. Aug. 5, 2014 - GlobeNewswire
Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies 10:55 a.m. Aug. 4, 2014 - PR Newswire - PRF
OXiGENE Announces Second Quarter 2014 Earnings Conference Call and Webcast 3:31 p.m. July 23, 2014 - GlobeNewswire
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity 7:15 a.m. June 25, 2014 - PR Newswire - PRF
A New Breed of Targeted Cancer Therapeutics & Stem Cell Advancements; Effective ProDrug Therapeutics Approach for GenSpera 7:29 a.m. June 20, 2014 - PR Newswire - PRF
Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors 7:01 a.m. June 17, 2014 - BusinessWire - BZX
OXiGENE, Inc. Announces $16 Million At-The-Market Registered Direct Offering 8:01 a.m. May 23, 2014 - GlobeNewswire
OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as President and Chief Executive Officer 7:32 a.m. May 16, 2014 - GlobeNewswire
OXiGENE Reports First Quarter 2014 Financial Results 3:01 p.m. May 6, 2014 - GlobeNewswire
OXiGENE Announces First Quarter 2014 Earnings Conference Call and Webcast 3:31 p.m. April 22, 2014 - GlobeNewswire
Stocks Review on Top Gainers -- Research on Uranium Energy, EarthLink Holdings, Tarena Intl., and OXiGENE 7:26 a.m. April 22, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CHiQ Secures AI Award, Elevates Smart Home Living

CHiQ's Big Win in the AI Game In a world where technology rarely stops spinning, CHiQ has carved its own commendable niche. Snagging the AI Home Ecosystem Brand Award at IFA 2026 in Berlin, the brand's knack for pioneering AI tech isn't just a footnote—it's the whole story. The award—enough to make your competitors green with envy—highlights how far they've come in...

Hyundai's Revolutionary US Steel Mill Set for 2029 Rollout

Hyundai's Major Steel Move: A Multibillion-Dollar Stake The steel industry scene in the U.S. just got a lot hotter with Hyundai's announcement of a $5.8 billion Electric Arc Furnace-based integrated steel mill in Louisiana. This game-changing project isn’t just a headline; it’s a concrete step towards beefing up the U.S. manufacturing backbone. Talk about...

Virterion Surges Ahead in VPS Racing With Reliable Hosting

Why Virterion Stands Out in 2026 VPS Landscape For anyone knee-deep in the hosting game, you know the market's got more players than a late-night poker round. Virterion, though—that's a name carving out a noticeable niche, and for solid reasons. In 2026, the backdrop's not just speed, it’s about matching technology and support with what ambitious developers need. VPS...

Testing Grounds: Navigating PRN Test Insights

Deciphering the PRN Tester Repetition Today we're staring at what feels like déjà vu—a simple PR test peppered with the classic sentence about a fox and a dog. It's like someone left the 'repeat' function stuck on during a slow day at the office. But hey, let’s dig in. Is there something more behind this repetitive text, or are we grumbling at a wall? Unpacking the...

Hisense Showcases AI in Everyday Living at IFA 2026

Hisense's Vision: An AI Utopia for Home Take this in: Hisense is cooking something bold at IFA 2026. They're pushing the envelope by integrating AI into our daily grind, promising to change the way we interact with the spaces that matter most. No more just dreaming about futuristic homes—these guys seem dead set on making them our everyday reality. Connected...

UGREEN's AI Hub: Privacy-First Tech for Smart Homes

UGREEN's Big AI Leap In the bustling scene of home tech evolution, UGREEN's throwing its hat in the ring with its latest offerings. They've just rolled out the UGREEN HomeAgent series, aiming to redefine what we think of when it comes to smart living. UGREEN, usually known for its tech gadgets, is diving headfirst into the smart home pool. These local AI hubs blend tech...

Labcorp Faces Lawsuit: Wiretapping Accusations Surface

Labcorp's Legal Tangle Unveiled One minute you're on Labcorp's website searching for medical info, the next you're caught up in a class-action legal whirlwind. Legal drama is not on any patient’s checklist, but here we are, with Labcorp knee-deep in some serious allegations. The crux of the matter points to alleged wiretapping violations, with claims that Labcorp,...

Freeport-McMoRan Hit with Legal Probe: What's Next?

Investigating the Movers and Shakers at Freeport When legal hawks like Kahn Swick & Foti, LLC sink their teeth into something, you can bet it's not just to nibble. These folks have jumped headfirst into probing Freeport-McMoRan Inc. (NYSE:FCX), ready to dismantle any smoke screens that might have been thrown up after the unfortunate Grasberg Block Cave mine incident. The...

Nocpix's Evolution: New Thermal Riflescope Unveiled

Raising the Thermal Image Bar When Nocpix, known for cutting-edge electro-optical tech, teases a new thermal riflescope, it's time for hunters to perk up. This ain't just another gadget. We're talking about equipment that elevates precision and brings an edge to the field. Scheduled for hunters who mean business, this next-gen scope is destined to redefine what it means...

Sarepta Under Scrutiny: KSF's Investigation Deepens

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...